Peter Piot
Showing 1–3 of 3 transcripts.
- Goldman Sachs25 min
Professor Peter Piot, Director of the London School of Hygiene and Tropical Medicine
The World Health Organization has classified the emerging coronavirus as a global emergency after transmission spread to nearly 30 countries through both travel and community contact. With no vaccine or specific treatment available, containment relies on isolation and surveillance, though data interpretation remains complicated by shifting case definitions and the virus's high respiratory transmissibility. While vaccine candidates from companies like Sanofi and J&J are in development, experts warn that the outbreak could trigger a second wave upon social reopening and underscore the urgent need for sustained investment in global public health infrastructure.
- Milken Institute1h 2m
Outsmarting Superbugs: What Are the Alternatives?
Margaret Hamburg, Matthew Hepburn, Peter Jackson, Nancy Knight, Jeanette Mucha, Peter Piot, Peggy Hamburg, David Wallace, Lance Price
Global leaders and organizations including the WHO, CDC, and the U.K. government are coordinating a multi-faceted response to antimicrobial resistance, which threatens to cause 10 million annual deaths by 2050 and mimic the 2008 financial crisis through massive economic losses. Innovative initiatives such as the CDC's AMR Challenge, Carb-X's $80 million funding for 40 development projects, and the U.K.'s "pull incentive" trial aim to revitalize the antibiotic pipeline by supporting SMEs and rewarding disease prevention rather than sales volume. Despite these advances, experts warn that rigid intellectual property laws, inadequate wastewater treatment, and capital gaps in microbiome startups hinder the deployment of new therapies needed to combat untreatable superbugs like drug-resistant tuberculosis.
- Milken Institute56 min
Superbugs: Avoiding an Existential Threat to Humanity
Esther Krofah, Valeria Bortolaia, Ron Daniels, Peter Jackson, Peter Piot, Lance Price, Sneha Kemka
This analysis details the critical global escalation of antimicrobial resistance, which currently causes 700,000 annual deaths and threatens to reach 10 million by 2050 without urgent intervention. The event highlights a pharmaceutical market failure where major drug withdrawals have shifted innovation to undercapitalized SMEs, necessitating new economic incentives like the UK's pilot pull mechanism to fund R&D. Strategic solutions prioritize infection control, agricultural bans on growth promoters, and precision diagnostics to bridge the gap between scientific discovery and clinical application.